1. Бобылев А.А., Рачина С.А., Эйдельштейн И.А. [и др.] Описание вспышки инфекции, вызванной Mycoplasma pneumoniae, в Смоленской области // Пульмонология. 2013. Т. 5. С. 97-100.
2. Эйдельштейн И.И., Эйдельштейн М.В., Романов А.В. [и др.] Оценка распространенности «классических» механизмов устойчивости к фторхинолонам у Chlamydia trachomatis, связанных с мутациями в генах топоизомераз // Клиническая микробиология и антимикробная химиотерапия. 2014. Т. 16, № 4. С. 301-307.
3. Averbuch D., Hidalgo-Grass C., Moses A. [et al.] Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010 // Emerging Infectious Diseases (Centers for Disease Control and Prevention). 2011. Vol. 17, No. 6. P. 1079-1082.
4. Clinical and Laboratory Standards Institute. 2011. Methods for antimicrobial susceptibility testing of human mycoplasmas. Approved Guideline M43-A. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Dumke R., von Baum H., Lück P [et al.] Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany // Eur. J. Clin. Microbiol. Infect. Dis. 2010. Vol. 16, No. 6. P. 613-616.
6. Dumke R., Stolz S., Jacobs E. [et al.] Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia // Int. J. Infect. Dis. 2014. Vol. 29. P. 197-199.
7. Godron A., Pereyre S., Monet C. [et al.] Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection // Pediatr. Nephrol. 2013. Vol. 28, No. 10. P. 2057-2060.
8. Hantz S., Garnier F., Peuchant O. [et al.] Multilocus variablenumber tandem-repeat analysis-confirmed emergence of a mac-rolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child // Journal of Clinical Microbiology. 2012. Vol. 50, No. 10. P 3402-3405.
9. Li X., Atkinson T., Hagood J. [et al.] Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates // Pediatric Infectious Disease Journal. 2009. Vol. 28, No. 8. P. 693-696.
10. Mayumi M., Mitsuo N., Norio O. [et al.] Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan // Antimicrob. Agents Chemother. 2004. Vol. 48, No. 12. P. 4624-4630.
11. Mulholland S., Gavranich J., Gillies M., Chang A.B. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children // Cochrane Database Syst. Rev. 2012. Vol. 12, No. 9. https://doi.org/10.1002/14651858.CD004875.pub4.
12. Peuchant O., Ménard A., Renaudin H. [et al.] Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis // Journal of Antimicrobial Chemotherapy. 2009. Vol. 64, No. 1. P. 52-58.
13. Spuesens E., Hoogenboezem T., Sluijter M. [et al.] Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing // J. Microbiol. Methods. 2010. Vol. 82, No. 3 P. 214-222
14. Spuesens E., Meijer A., Bierschenk D. [et al.] Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in The Netherlands // Journal of Clinical Microbiology. 2012. Vol. 50, No. 6. P. 1999-2004.
15. Waites K., Talkington D. Mycoplasma pneumoniae and its role as a human pathogen // Clin. Microbiol. Rev. 2004. Vol. 17, No. 4. P. 697-728.